Assertio Holdings Acquires Spectrum Pharmaceuticals

April 25, 2023

Assertio Holdings, Inc. agreed to acquire all outstanding shares of Spectrum Pharmaceuticals, Inc. in an all-stock transaction with contingent value rights (CVRs), expected to close in Q3 2023. The deal combines Assertio's digital, non-personal commercial capabilities with Spectrum's in-person commercial team and ROLVEDON (eflapegrastim-xnst) to accelerate the product's launch and broaden the combined company's pharmaceutical portfolio.

Buyers
Assertio Holdings, Inc.
Targets
Spectrum Pharmaceuticals, Inc.
Sellers
Spectrum stockholders
Industry
Pharmaceuticals
Location
Massachusetts, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.